Comparison of Ferric Sodium EDTA in Combination with Vitamin C, Folic Acid, Copper Gluconate, Zinc Gluconate, and Selenomethionine as Therapeutic Option for Chronic Kidney Disease Patients with Improvement in Inflammatory Status

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

The aim of this study was to evaluate the use of the new oral formulation based on ferric sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate, and selenomethionine (Ferachel Forte®) in patients with moderate CKD and functional IDA, analyzing the inflammatory status in addition to iron blood parameters, in comparison with oral ferrous sulfate and liposomal iron therapies.

Why It Was Studied

Sixty-two elderly patients were randomly allocated to one of the following oral treatments for 6 months: ferrous sulfate (Group 1; N = 20), ferric sodium EDTA in combination (Group 2; N = 22), and ferric liposomal formulation (Group 3; N = 20).

The evaluated parameters included iron profile parameters of hemoglobin (Hb), sideremia, ferritin, transferrin saturation, C-reactive protein (CRP), and hepcidin.

Who Took Part

The study group was 2 patients.

The age groups tagged for this paper are older adults.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

The methods mention a period of 6 months.

What Was Measured

The evaluated parameters included iron profile parameters of hemoglobin (Hb), sideremia, ferritin, transferrin saturation, C-reactive protein (CRP), and hepcidin.

The subject headings attached to it are Anemia, Iron-Deficiency, Antioxidants, Ascorbic Acid, Edetic Acid, Folic Acid, Gluconates and Hepcidins.

The authors tagged it with the keywords C-reactive protein, chronic kidney disease, ferric sodium EDTA, ferritin, inflammation and iron deficiency anemia.

What This Means in Plain Language

The paper is a randomized study of Copper (Supplement) in 2 patients over 6 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2022 (Nutrients), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.